Correlation between prescribing quality and pharmaceutical costs in English primary care: National cross-sectional analysis

British Journal of General Practice

Volumn 61, Issue 590, 2011, Pages

  Fleetcroft, Robert ^a   Cookson, Richard ^b   Steel, Nicholas ^a   Howe, Amanda ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Cost effectiveness; Economics, pharmaceutical; Primary health care; Quality indicators; Quality of health care

Indexed keywords

ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; DATA BASE; DRUG COST; GENERAL PRACTICE; HUMAN; HYPERTENSION; INFLUENZA VACCINATION; OBSERVATIONAL STUDY; PRESCRIPTION; PRIMARY MEDICAL CARE; QUALITY CONTROL; SMOKING CESSATION;

COST-BENEFIT ANALYSIS; CROSS-SECTIONAL STUDIES; DRUG COSTS; ENGLAND; FAMILY PRACTICE; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTION DRUGS; QUALITY INDICATORS, HEALTH CARE; QUALITY OF HEALTH CARE;

EID: 83455212257     PISSN: 09601643     EISSN: None     Source Type: Journal    
DOI: 10.3399/bjgp11X593839     Document Type: Article

References (25)

1. Department of Health. A first class service: quality in the new NHS. London: DOH, 1998. http://www.dh.gov.uk/en/Publicationsandstatistics/ Publications/PublicationsPolicyAndGuidance/DH-4006902 (accessed 21 Jul 2011).
2. Chapman S, Durieux P, Walley T. Good prescribing practice. In Mossialos E, Mrazek M, Walley T (eds). Regulating pharmaceuticals in Europe: striving for efficiency, equity and quality. Maidenhead: Open University Press, 2004.
3. Audit Commission. A prescription for improvement: towards more rational prescribing in general practice. London: HMSO, 1994.
4. NHS Executive. NHS performance indicators. London: Department of Health, 2000. http://www.performance.doh.gov.uk/nhsperformanceindicators/hlpi2000/ h1117s.html (accessed 21 Jul 2011).
5. Department of Health. Equity and excellence: liberating the NHS. London: DOH, 2010. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-117353 (accessed 21 Jul 2011).
6. National Prescribing Centre and the National Primary Care Research and Development Centre. Modernising Medicines Management. A guide to achieving benefits for patients, professionals and the NHS (book 2). Liverpool: NPC, 2002. http://www.pdptoolkit.co.uk/files/ppa/mmm-guide-2.pdf (accessed 10 Aug 2011).
7. Ward P, Noyce P, St Leger AS. Are GP practice prescribing rates for coronary heart disease drugs equitable? A cross sectional analysis in four primary care trusts in England. J Epidemiol Community Health 2004; 58(2): 89-96. (Pubitemid 38130474)
8. Fleetcroft R, Cookson R. The relationship between prescribing expenditure and quality in primary care: an observational study. Br J Gen Pract 2006; 56(529): 613-619. (Pubitemid 44209985)
9. McGlynn ES, Asch J, Adams J, et al. The quality of health care delivered to adults in the USA. N Engl J Med 2003; 348(26): 2635-2645. (Pubitemid 36741592)
10. Fisher E, Wennberg DE, Stukel TA, et al. The implications of regional variations in Medicare Spending Part 2: health outcomes and satisfaction with care. Ann Intern Med 2003; 138(4): 297.
11. NHS Confederation. New General Medical Services Contract 2003. Investing in general practice. London: NHS Confederation, 2003.
12. Walker S, Mason A, Claxton K, et al. Value for money and the quality and outcomes framework in primary care in the NHS. Br J Gen Pract 2010; 60(574): 352-357.
13. Fleetcroft R, Parekh-Bhurke S, Howe AC, et al. The pay-for-performance programme in primary care: estimation of population mortality reduction in England. Br J Gen Pract 2010; 60(578): 649-654.
14. Guthrie B. Measuring the quality of healthcare systems using composites. BMJ 2008; 337: a639.
15. Schleinitz MD, Weiss JP, Owens DK. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis. Am J Med 2004; 116(12): 797-806. (Pubitemid 38721321)
16. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373(9678): 1849-1860.
17. National Institute for Health and Clinical Excellence. Anxiety: management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care. CG22. 2004. http://guidance.nice.org.uk/CG22 (accessed 10 Aug 2011).
18. British National Formulary. BNF 51. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2006.
19. Allsup S, Haycox A, Regan M, Gosney M. Is influenza vaccination cost effective for healthy people between ages 65 and 74 years? A randomised controlled trial. Vaccine 2004; 23(5): 639-645. (Pubitemid 39473193)
20. National Institute for Health and Clinical Excellence. NICE Technology Appraisal No 94: Statins for the prevention of cardiovascular events. London: NICE, 2006. http://www.nice.org.uk/nicemedia/pdf/TA094guidance.pdf (accessed 21 Jul 2011).
21. Ray K, Seshasai, Sever P, et al. Statins and all-cause mortality in high-risk primary prevention. Arch Intern Med 2010; 170(12): 1024-1031.
22. Campbell SM, Cantrill JA, Roberts D. Prescribing indicators for UK general practice: Delphi consultation study. BMJ 2000; 321(7258): 425-428. (Pubitemid 30609449)
23. McLean G, Sutton M, Guthrie B. Deprivation and quality of primary care services: evidence for persistence of the inverse care law from the UK Quality and Outcomes Framework. J Epidemiol Community Health 2006; 60(11): 917-922. (Pubitemid 44690078)
24. Steel N, Bachmann MO, Maisey S, et al. Self-reported receipt of care consistent with 32 quality indicators: a national population survey of adults over 50 years old in England. BMJ 2008; 337: a957.
25. Audit commission 2007. Prescribing costs in primary care. National Audit office. http://www.nao.org.uk/publications/0607/prescribing-costs-in-primary-c. aspx (accessed 21 Jul 2011).